These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18550931)

  • 1. ONTARGET: questions asked, questions answered.
    Weber MA
    J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteinuria: Is the ONTARGET renal substudy actually off target?
    Ruggenenti P; Remuzzi G
    Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
    [No Abstract]   [Full Text] [Related]  

  • 3. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
    Burnier M; Waeber B; Hess O; Lüscher T
    Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons learned from the ONTARGET and TRANSCEND trials.
    Basile J
    Curr Atheroscler Rep; 2009 Sep; 11(5):371-6. PubMed ID: 19664381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 7. Telmisartan, ramipril, or both in patients at high risk of vascular events.
    Büchner N; Banas B; Krämer BK
    N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
    [No Abstract]   [Full Text] [Related]  

  • 8. New data on ONTARGET: more confusion?
    Escobar C; Echarri R; Barrios V
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
    [No Abstract]   [Full Text] [Related]  

  • 9. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 11. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].
    Liakishev AA
    Kardiologiia; 2008; 48(5):72. PubMed ID: 18537808
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
    Guthrie R
    Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
    Liebson PR; Amsterdam EA
    Prev Cardiol; 2009; 12(1):43-50. PubMed ID: 19301691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):14, 16. PubMed ID: 18983047
    [No Abstract]   [Full Text] [Related]  

  • 19. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
    Düsing R; Nitschmann S
    Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
    Sleight P
    J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.